CUSTOM DERMATOLOGY SEARCH:
Current Concepts in the Treatment of Recurrent Aphthous Stomatitis
A. Altenburg, MD; C. C. Zouboulis, MD
Idiopathic aphthae are the most frequently occurring inflammatory lesions of the oral mucous membrane. Nosologically, the condition is clearly defined, but the sores are often difficult to differentiate from heterogeneously similar aphthoid ulcerations and mucosal erosions. Episodic aphthous attacks are characterized by painful lesions that range from the size of a pinhead up to several centimeters. Fibrin covered ulcerations with a hyperemic halo are typically visible on the oral mucous membrane, but they rarely appear in the genital region. Spontaneous healing is possible after many years.
Dietary and General Measures
Certain foods should be avoided as they appear to trigger the eruption of new aphthae and prolong the course of the lesions (e.g., foods that are hard, acidic, salty, or spicy, as well as nuts, chocolate, citrus fruits, and alcoholic or carbonated beverages). In addition, because surfactants and detergents can cause irritation, dental care products containing sodium lauryl sulphate should be avoided.4
Pain relief can be attained using topical lidocaine 2% gel or spray, polidocanol adhesive dental paste, or benzocaine lozenges. Available combination preparations include a pump spray with tetracaine and polidocanol, and a mouth rinse solution that uses benzocaine and cetylpyridinium chloride as the active ingredients. As well, anesthetic-containing solutions, e.g., a viscous lidocaine 2% solution, can be applied carefully on the lesions.
Antiseptic and Anti-inflammatory Therapies
Mouth washes with ingredients known to mildly inhibit inflammation can be used, e.g., chamomile extract solution (Kamillosanģ, MEDA Pharma). Research has shown that the use of chlorhexidine (CHX) mouth rinses on RAS may be particularly helpful.5 Other dosing forms of CHX include dental gels or throat sprays. Triclosan is a broad spectrum antibacterial agent that also exhibits antiseptic, anti-inflammatory, and analgesic effects. Available formulations include toothpastes and mouthrinses. A randomized, double-blind study that explored the topical application of diclofenac 3% in hyaluronan 2.5% reported a significant reduction in pain.6 For adjuvant therapy, dexpanthenol, which acts as an humectant, emollient, and moisturizer, can be used in different application forms and is available without prescription.
Applications of hydrogen peroxide 0.5% solution, silver nitrate 1%-2% solution, or a silver nitrate caustic stick represent several older therapeutic methods that can reduce the duration of solitary aphthae. Cauterizing chemical treatments must be administered by a dentist or physician to avoid burning healthy tissues.
Localized therapy with tetracycline can effectively reduce the duration and pain of oral aphthae.7 To avoid difficulties related to the chemical stability of tetracycline when it is formulated in an aqueous solution, a prescription for compounding and preparation, as shown in Table 1, has been proposed.8 Due to acidic pH values, patients may experience a brief burning sensation, but contact sensitization has not been reported in the context of intra-oral topical tetracycline applications. Marked improvement has been described with the use of a dental paste containing chlortetracycline 3%.9
Topical sucralfate is effective in treating RAS ulcerations when administered at 5mL, 4 times/day. Sucralfate exerts a soothing effect on lesions by adhering to mucous membrane tissues and forming a protective barrier on the affected site. This drug is commonly used to treat peptic ulcers.
Topical steroids, such as triamcinolone acetonide and prednisolone (2 times/day), are formulated as oral pastes, and are commonly used in the management of RAS. Additionally, therapeutic benefit can be derived from a mouthwash containing betamethasone. Of concern is the fact that the long-term use of steroids may predispose patients to developing local candidiasis. Combination therapy with a topical anesthetic during the day and a steroid paste at night is widely accepted as the optimal treatment regimen. An intralesional injection of triamcinolone (0.1-0.5mL per lesion) can be considered for painful single aphthae. For the treatment of genital aphthous ulcers, a combination of fluorinated steroids and antiseptics that are formulated in a cream base can be effective (e.g., dexamethasone 0.1% + chlorhexidine 1% or flumetasone 0.02% + clioquinol 3%).
Application of 5-aminosalicylic acid 5% cream (applying a small amount to cover the aphthae 3 times/day), or a toothpaste containing amyloglucosidase and glucose oxidase can reduce pain and lessen the duration of oral aphthae.10 A topical prostaglandin E2 gel prevented the appearance of new aphthae in a short-term study involving a small number of patients.11 According to the experience of several patients, raw egg white may partially soften oral pain in RAS. Interestingly, the number of aphthae and frequency of recurrence are reduced during phases of smoking compared with phases of abstinence; experimental data confirmed the anti-inflammatory effect of nicotine and biochanin A on keratinocytes.12,13 Also, a small study showed the remission of aphthosis during therapy with chewable nicotine tablets.14
Colchicine has been shown to reduce the number and duration of lesions in up to 63% of patients with RAS.15 Treatment over 6 weeks, followed by long-term (years) therapy (1-2mg/day) is recommended. However, relapse following treatment discontinuation is common. Physicians must ensure that appropriate contraceptive methods are practiced by patients before initiating treatment. From our experience, combination therapy with colchicine and pentoxifylline, benzathine penicillin, immunosuppressants, or interferon-alpha (IFN-Š) is possible.
In uncontrolled studies, pentoxifylline (300mg, 1-3 times/day) was shown to be effective against orogenital aphthae. The response rates in children ranged between 36% and 63%.16
Systemic corticosteroids are used as rescue treatment in patients with acute exacerbation and in those who inadequately responded to therapy with colchicine and pentoxifylline. Oral prednisolone, or its equivalent, at 10-30mg/day for up to 1 month can be administered during an outbreak. From our experience, intravenous (IV) pulse therapy at 100mg/day for 3 days results in quick improvement for severe cases of RAS without the side-effects that are associated with long-term prednisolone use. Patient surveillance during therapy is advisable.
Dapsone (100mg/day) can be used for oral and genital aphthae, however, rapid relapses can occur after discontinuation of treatment. Intermittent administration of ascorbic acid and the reduction of smoking are useful in averting hematologic side-effects.17
Under standard (100-300mg/day) or low (50mg/day) dosing levels of thalidomide, a dose-dependent effect against orogenital ulcerations emerges within 7-10 weeks following treatment. Due to teratogenicity and other potentially severe side-effects, therapy should be reserved for exceptional cases, such as in patients with persistent peripheral neuropathy.
Antimetabolites (Azathioprine and Methotrexate)
Azathioprine (Imuranģ, GlaxoSmithKline) at 50-150mg/day can reduce the frequency and extent of severe orogenital aphthosis in ABD, as demonstrated in placebo-controlled studies.18 It is contraindicated for women who are pregnant or breastfeeding, and it is not recommended for use in pediatric patients. During treatment, blood cell count and liver function should be monitored. Methotrexate (7.5-20mg/week) has been proven to be effective in severe orogenital aphthosis. While on therapy, folic acid should be administered intermittently.
Cyclosporine A, at a dosage of 3-6mg/kg, was shown to be effective in about 50% of ABD patients with respect to aphthosis.19 However, abrupt withdrawal of therapy may lead to a rebound phenomenon. Due to the potential for severe side-effects from therapy, clinical and serologic vigilance must be observed.
Recombinant IFN-Š preparations, IFN-Š 2a and 2b, have not been tried for RAS; however, they have successfully treated ABD. A study evaluating the efficacy and safety of systemic IFN-Š in patients with ABD reported complete or partial remission of mucocutaneous lesions.20 Intermediate or high doses of IFN-Š 2a (6-9 x 106 units, 3 times/week) seemed to be more effective than the low dose (3 x 106 units 3 times/week). The low dose may be recommended for maintenance therapy if the treatment is shown to be effective within 1-4 months. Disease recurrences after stopping IFN therapy were common, but reinstatement of therapy also elicited a rapid response.
Infliximab (Remicadeģ, Centocor) at 5mg/kg IV can be administered at different time intervals. As early as several days following the first dose, rapid healing can occur, even in patients with refractory recurrent disease who exhibit both oral and genital ulcers. It is possible that relapses may not occur within the first 6 weeks of starting therapy. Etanercept (Enbrelģ, Amgen-Wyeth) at 25mg, twice weekly, given subcutaneously) appears to be effective on oral, but not on genital aphthae.21
Monotherapy with chlorambucil on orogenital ulcerations in ABD demonstrated a good response when administered at an initial dose of 0.1mg/kg, followed by a low maintenance dose of 2mg/day.22 Orogenital aphthae in ABD patients also improved when using pulse therapy combined with cyclophosphamide. Treatment with alkylating agents should be limited exclusively to patients with severe forms of systemic aphthosis.22
Other Systemic Therapies
In a study involving 13 patients, minocycline (100mg/day) was found to be effective in genital aphthosis, but it was ineffective against oral aphthosis.23 For the immunomodulator, levamisole, treatment at 150mg/day on 3 consecutive days/week during attacks has been occasionally reported to be effective against orogenital aphthae.24,25 Subcutaneous testosterone, administered once yearly, was shown to be effective in individual female patients who developed aphthae premenses.26 Also, oral contraceptives containing high levels of estrogen can be used successfully; improvement may be expected after 3-6 months.
Localized topical regimens are considered to be the standard treatment in mild cases of RAS. In more severe cases, topical therapies are likewise very useful in reducing the healing time, but they are often ineffective at prolonging disease-free intervals. For most patients with RAS, monotherapy with colchicine, or in combination with either pentoxifylline or the short-term use of prednisolone, is satisfactory. Furthermore, highly efficacious drugs from a wide spectrum of immunomodulatory agents are available. However, they should not be utilized without first cautiously weighing the risks and the benefits for each patient.
In this issue:
All content ©2004-2014 SkinTherapyLetter® |
Last modified: Wednesday, 06-Aug-2014 12:23:14 MDT